While a large-scale randomized placebo-controlled trial reported that the introduction of a GLP-1 RA (once-weekly semaglutide) significantly increased the risk of retinopathy complications (vitreous hemorrhage, blindness, or conditions requiring treatment with an intravitreal agent or photocoagulation) [27], conversely, we found no statistically significant difference regarding retinal biomarkers in the subgroup of patients for whom a GLP-1 RA had been introduced during hospitalization compared to patients treated with other antidiabetic drugs. The gene discussed is GLP1R; the disease is blindness (disorder).